[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

November 29, 2018
Original Investigation

Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.4951

This cohort study investigates the association between radiation doses in the parotid glands and self-reported xerostomia among adults treated with whole-brain radiation therapy.

Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5070

This Markov model study assesses the cost-effectiveness of capecitabine and bevacizumab maintenance therapy after induction chemotherapy for treatment of metastatic colorectal cancer.

Research Letter

Association Between Polycystic Ovary Syndrome and Cancer Risk

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5188

This cohort study of Swedish register data examines the association between polycystic ovary syndrome and cancer risk in females aged 15 to 50 years between 1985 and 2009.

Viewpoint

Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer—The Forgotten Dance Partner?

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5191

This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.

Comment & Response

Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5287

Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5296

Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma—Reply

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5293

Burden of Multiple Myeloma in Taiwan

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5523

Burden of Multiple Myeloma in Taiwan—Reply

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5533

Anlotinib for Refractory Advanced Non–Small Cell Lung Cancer in China

Abstract Full Text
JAMA Oncol. Published online November 29, 2018. doi:10.1001/jamaoncol.2018.5526
November 21, 2018
Original Investigation

Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.4934

This cohort study examines patient data in the European Society for Blood and Marrow Transplantation Registry for causes of death, risk factors, and overall survival rates among patients who received a second cancer diagnosis after being treated with stem cell transplant.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanA Phase 2 Single-Arm Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5080

This multicenter, phase 2, single-arm trial assesses the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type metastatic colorectal cancer who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy.

Research Letter

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and DexamethasoneFive-Year Follow-up of a Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5457

This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.

Review

Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell CarcinomaA Review

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.4604

This narrative review discusses the rationale and results of clinical trials in immunotherapy-based combination therapy for patients with advanced renal cell carcinoma.

Comment & Response

Circulating Tumor Cells and Radiotherapy Benefit in Early Breast Cancer

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5077

Circulating Tumor Cells and Radiotherapy Benefit in Early Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5108

Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5290

Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5299
November 15, 2018
Original Investigation

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality

Abstract Full Text
has audio
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.4836

This cohort study investigates whether treatment of Gleason score 9-10 prostate cancer with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (termed MaxRP) vs external beam radiotherapy, brachytherapy, and androgen deprivation therapy (termed MaxRT) was associated with prostate cancer–specific mortality and all-cause mortality risk.

Brief Report

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.4942

This cohort study investigates possible mechanisms underlying primary resistance to immune checkpoint inhibitors of metastatic colorectal cancers displaying microsatellite instability or mismatch repair deficiency.

JAMA Oncology Clinical Challenge

Hemifacial Hyperhidrosis in a Patient With an Apical Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.4597

This case report describes an unusual case of hyperhidrosis associated with apical lung cancer with sympathetic nerve involvement.

Cancer Care Chronicles

Cancer Care Chronicles—Social Media and Gender Equity in Oncology

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.4647

This article illustrates how social media can create new communities within medicine and, in particular, advance gender equity in oncology.

Comment & Response

Detecting a Survival Benefit to Dose Escalation

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.5055

Detecting a Survival Benefit to Dose Escalation—Reply

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.5093

Competing Risks for a Diagnosis of Invasive Breast Cancer

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.5058

Competing Risks for a Diagnosis of Invasive Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online November 15, 2018. doi:10.1001/jamaoncol.2018.5102
November 8, 2018
Original Investigation

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate CytologyA Prospective Blinded Multicenter Study

Abstract Full Text
open access
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.4616

This prospective study examines the diagnostic accuracy of a multigene genomic classifier test for diagnosis of benign disease or cancer in thyroid nodules with indeterminate cytology.

Brief Report

Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical ResectionA Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.4610

This exploratory secondary analysis of a randomized clinical trial evaluated local control of brain metastases among patients treated with stereotactic radiosurgery vs surgical resection in the European Organization for the Research and Treatment of Cancer 22952-26001 phase 3 trial.

Viewpoint

Is Precision Medicine an Oxymoron?

Abstract Full Text
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.5099

This Viewpoint discusses the initials results of the NCI-MATCH trial, a phase 2 study that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type.

JAMA Oncology Patient Page

Palliative Care

Abstract Full Text
free access
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.4962

This Patient Page defines palliative care and explains who may most benefit, when it is most appropriate, and which clinicians might help administer it.

Comment & Response

Moving Precision Oncology Forward Amid Myths and Misconceptions

Abstract Full Text
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.5064

Moving Precision Oncology Forward Amid Myths and Misconceptions

Abstract Full Text
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.5067

Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply

Abstract Full Text
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.5111
November 1, 2018
Original Investigation

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCCThe Phase 2 CONDOR Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4628

This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal TumorThe PERSIST-5 Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4060

This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.

Brief Report

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4640

This study searched ClinicalTrials.gov to examine the reporting rates of research biopsies conducted in oncology clinical trials amd investigates what factors correlate with research biopsy reporting.

Research Letter

Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.5090

This retrospective observational analysis of health claims data compares the safety, effectiveness, and cost of biosimilar filgrastim and filgrastim.

Viewpoint

Hypofractionated Nodal Irradiation for Breast CancerA Case for Caution

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.5061

This Viewpoint discusses the use of hypofractionation for regional nodal irradiation as part of radiotherapy for breast cancer and the importance of waiting for results of long-term prospective studies.

Poetry and Oncology

White Noise

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4644
Comment & Response

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4931

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.4959

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance?

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.5116

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance—Reply

Abstract Full Text
JAMA Oncol. Published online November 1, 2018. doi:10.1001/jamaoncol.2018.5105
×